Scott Peter Webster
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Scott Peter Webster has a total of 345 co-authors. Here are the top co-authors by number of shared publications:
Margaret Binnie
Centre for Cardiovascular Science, University of Edinburgh, Queen's Medical Research Institute, EH16 4TJ, United Kingdom
17 shared publicationsBrian R. Walker
Centre for Cardiovascular Science (A.E.C., T.M.J.K., Z.Z., C.L.E., J.S.G., S.P.W., B.R.W., J.R.S., K.E.C.) and Medical Research Council Centre for Inflammation Research (A.E.C., C.D.L., J.S.G., J.H., J.S.S., A.G.R.), Queen's Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom
12 shared publications- Damian James Mole
Centre for Inflammation Research, Institute for Regeneration and Repair, Edinburgh Bioquarter, The University of Edinburgh
11 shared publications Jonathan R. Seckl
Centre for Cardiovascular Science (A.E.C., T.M.J.K., Z.Z., C.L.E., J.S.G., S.P.W., B.R.W., J.R.S., K.E.C.) and Medical Research Council Centre for Inflammation Research (A.E.C., C.D.L., J.S.G., J.H., J.S.S., A.G.R.), Queen's Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom
11 shared publicationsAndrew McBride
Centre for Cardiovascular Science, University of Edinburgh, Queen's Medical Research Institute, EH16 4TJ, United Kingdom
10 shared publications- Dominic James Campopiano
School of Chemistry, University of Edinburgh, Edinburgh, UK
6 shared publications
Latest Publications
- Open Access
- 28 December 2023
- Published by Wiley in British Journal of Pharmacology
- Vol. 181 (8) , 1256-1267
5α‐Tetrahydrocorticosterone: A topical anti‐inflammatory glucocorticoid with an improved therapeutic index in a murine model of dermatitis
Background and Purpose: Glucocorticoids are powerful anti‐inflammatory drugs, but are associated with many side‐effects. Topical application in atopic dermatitis leads to skin thinning, metabolic changes, and adrenal suppression. 5α‐Tetrahydrocorticosterone (5αTHB) is a potential selective anti‐inflammatory with reduced metabolic effects. Here, the efficacy and side‐effect profile of 5αTHB were compared with hydrocortisone in preclinical models of irritant dermatitis.Experimental Approach: Acute irritant dermatitis was invoked in ear skin of male C57BL/6 mice with a single topical application of croton oil. Inflammation was assessed as oedema via ear weight following treatment with 5αTHB and hydrocortisone. Side‐effects of 5αTHB and hydrocortisone were assessed following chronic topical steroid treatment (28 days) to non‐irritated skin. Skin thinning was quantified longitudinally by caliper measurements and summarily by qPCR for transcripts for genes involved in extracellular matrix homeostasis; systemic effects of topical steroid administration also were assessed. Clearance of 5αTHB and hydrocortisone were measured following intravenous and oral administration.Key Results: 5αTHB suppressed ear swelling in mice, with ED50 similar to hydrocortisone (23 μg vs. 13 μg). Chronic application of 5αTHB did not cause skin thinning, adrenal atrophy, weight loss, thymic involution, or raised insulin levels, all of which were observed with topical hydrocortisone. Transcripts for genes involved in collagen synthesis and stability were adversely affected by all doses of hydrocortisone, but only by the highest dose of 5αTHB (8× ED50). 5αTHB was rapidly cleared from the systemic circulation.Conclusions and Implications: Topical 5αTHB has potential to treat inflammatory skin conditions, particularly in areas of delicate skin.
- 28 December 2023
- Published by Wiley in British Journal of Pharmacology
- Vol. 181 (8) , 1256-1267
Open Access5α‐Tetrahydrocorticosterone: A topical anti‐inflammatory glucocorticoid with an improved therapeutic index in a murine model of dermatitis
Background and Purpose: Glucocorticoids are powerful anti‐inflammatory drugs, but are associated with many side‐effects. Topical application in atopic dermatitis leads to skin thinning, metabolic changes, and adrenal suppression. 5α‐Tetrahydrocorticosterone (5αTHB) is a potential selective anti‐inflammatory with reduced metabolic effects. Here, the efficacy and side‐effect profile of 5αTHB were compared with hydrocortisone in preclinical models of irritant dermatitis.Experimental Approach: Acute irritant dermatitis was invoked in ear skin of male C57BL/6 mice with a single topical application of croton oil. Inflammation was assessed as oedema via ear weight following treatment with 5αTHB and hydrocortisone. Side‐effects of 5αTHB and hydrocortisone were assessed following chronic topical steroid treatment (28 days) to non‐irritated skin. Skin thinning was quantified longitudinally by caliper measurements and summarily by qPCR for transcripts for genes involved in extracellular matrix homeostasis; systemic effects of topical steroid administration also were assessed. Clearance of 5αTHB and hydrocortisone were measured following intravenous and oral administration.Key Results: 5αTHB suppressed ear swelling in mice, with ED50 similar to hydrocortisone (23 μg vs. 13 μg). Chronic application of 5αTHB did not cause skin thinning, adrenal atrophy, weight loss, thymic involution, or raised insulin levels, all of which were observed with topical hydrocortisone. Transcripts for genes involved in collagen synthesis and stability were adversely affected by all doses of hydrocortisone, but only by the highest dose of 5αTHB (8× ED50). 5αTHB was rapidly cleared from the systemic circulation.Conclusions and Implications: Topical 5αTHB has potential to treat inflammatory skin conditions, particularly in areas of delicate skin.
- 10 June 2023
- Published by Springer Nature in Diabetologia
- Vol. 66 (9) , 1735-1747
Memory deficits in a juvenile rat model of type 1 diabetes are due to excess 11β-HSD1 activity, which is upregulated by high glucose concentrations rather than insulin deficiency
Aims/hypothesis Children with diabetes may display cognitive alterations although vascular disorders have not yet appeared. Variations in glucose levels together with relative insulin deficiency in treated type 1 diabetes have been reported to impact brain function indirectly through dysregulation of the hypothalamus–pituitary–adrenal axis. We have recently shown that enhancement of glucocorticoid levels in children with type 1 diabetes is dependent not only on glucocorticoid secretion but also on glucocorticoid tissue concentrations, which is linked to 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity. Hypothalamus–pituitary–adrenal axis dysfunction and memory alteration were further dissected in a juvenile rat model of diabetes showing that excess 11β-HSD1 activity within the hippocampus is associated with hippocampal-dependent memory deficits. Here, to investigate the causal relationships between diabetes, 11β-HSD1 activity and hippocampus-dependent memory deficits, we evaluated the beneficial effect of 11β-HSD1 inhibition on hippocampal-related memory in juvenile diabetic rats. We also examined whether diabetes-associated enhancement of hippocampal 11β-HSD1 activity is due to an increase in brain glucose concentrations and/or a decrease in insulin signalling. Methods Diabetes was induced in juvenile rats by daily i.p. injection of streptozotocin for 2 consecutive days. Inhibition of 11β-HSD1 was obtained by administrating the compound UE2316 twice daily by gavage for 3 weeks, after which hippocampal-dependent object location memory was assessed. Hippocampal 11β-HSD1 activity was estimated by the ratio of corticosterone/dehydrocorticosterone measured by LC/MS. Regulation of 11β-HSD1 activity in response to changes in glucose or insulin levels was determined ex vivo on acute brain hippocampal slices. The insulin regulation of 11β-HSD1 was further examined in vivo using virally mediated knockdown of insulin receptor expression specifically in the hippocampus. Results Our data show that inhibiting 11β-HSD1 activity prevents hippocampal-related memory deficits in diabetic juvenile rats. A significant increase (53.0±9.9%) in hippocampal 11β-HSD1 activity was found in hippocampal slices incubated in high glucose conditions (13.9 mmol/l) vs normal glucose conditions (2.8 mmol/l) without insulin. However, 11β-HSD1 activity was not affected by variations in insulin concentration either in the hippocampal slices or after a decrease in hippocampal insulin receptor expression. Conclusions/interpretation Together, these data demonstrate that an increase in 11β-HSD1 activity contributes to memory deficits observed in juvenile diabetic rats and that an excess of hippocampal 11β-HSD1 activity stems from high glucose levels rather than insulin deficiency. 11β-HSD1 might be a therapeutic target for treating cognitive impairments associated with diabetes. Graphical Abstract
- 10 June 2023
- Published by Springer Nature in Diabetologia
- Vol. 66 (9) , 1735-1747
Memory deficits in a juvenile rat model of type 1 diabetes are due to excess 11β-HSD1 activity, which is upregulated by high glucose concentrations rather than insulin deficiency
Aims/hypothesis Children with diabetes may display cognitive alterations although vascular disorders have not yet appeared. Variations in glucose levels together with relative insulin deficiency in treated type 1 diabetes have been reported to impact brain function indirectly through dysregulation of the hypothalamus–pituitary–adrenal axis. We have recently shown that enhancement of glucocorticoid levels in children with type 1 diabetes is dependent not only on glucocorticoid secretion but also on glucocorticoid tissue concentrations, which is linked to 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity. Hypothalamus–pituitary–adrenal axis dysfunction and memory alteration were further dissected in a juvenile rat model of diabetes showing that excess 11β-HSD1 activity within the hippocampus is associated with hippocampal-dependent memory deficits. Here, to investigate the causal relationships between diabetes, 11β-HSD1 activity and hippocampus-dependent memory deficits, we evaluated the beneficial effect of 11β-HSD1 inhibition on hippocampal-related memory in juvenile diabetic rats. We also examined whether diabetes-associated enhancement of hippocampal 11β-HSD1 activity is due to an increase in brain glucose concentrations and/or a decrease in insulin signalling. Methods Diabetes was induced in juvenile rats by daily i.p. injection of streptozotocin for 2 consecutive days. Inhibition of 11β-HSD1 was obtained by administrating the compound UE2316 twice daily by gavage for 3 weeks, after which hippocampal-dependent object location memory was assessed. Hippocampal 11β-HSD1 activity was estimated by the ratio of corticosterone/dehydrocorticosterone measured by LC/MS. Regulation of 11β-HSD1 activity in response to changes in glucose or insulin levels was determined ex vivo on acute brain hippocampal slices. The insulin regulation of 11β-HSD1 was further examined in vivo using virally mediated knockdown of insulin receptor expression specifically in the hippocampus. Results Our data show that inhibiting 11β-HSD1 activity prevents hippocampal-related memory deficits in diabetic juvenile rats. A significant increase (53.0±9.9%) in hippocampal 11β-HSD1 activity was found in hippocampal slices incubated in high glucose conditions (13.9 mmol/l) vs normal glucose conditions (2.8 mmol/l) without insulin. However, 11β-HSD1 activity was not affected by variations in insulin concentration either in the hippocampal slices or after a decrease in hippocampal insulin receptor expression. Conclusions/interpretation Together, these data demonstrate that an increase in 11β-HSD1 activity contributes to memory deficits observed in juvenile diabetic rats and that an excess of hippocampal 11β-HSD1 activity stems from high glucose levels rather than insulin deficiency. 11β-HSD1 might be a therapeutic target for treating cognitive impairments associated with diabetes. Graphical Abstract
- 18 October 2021
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 77
Hepatic choline deficiency underpins amelioration of visceral obesity and diabetes in ectonucleotide pyrophosphatase (Enpp)-6-/- mice
The global prevalence of obesity continues to rise, creating a growing need for new effective medicines. Selective targeting of visceral obesity (fat around the internal organs) would be particularly advantageous because it carries a greater risk for cardiometabolic diseases. The ectonucleotide pyrophosphatase (ENPP) enzyme family participates in several pathological conditions including diabetes (ENPP1, and ENPP2, also known as autotaxin) and vascular dysfunction (ENPP3-4). Of these, ENPP6 is a lysophospholipase-C-type enzyme recently linked to regulation of local phosphocholine availability. The role of ENPP6 in fat distribution and metabolism in the context of obesity is unknown. Here we investigated the metabolic profile of mice lacking the Enpp6 gene (Enpp6/) when exposed to an obesogenic high-fat-diet (HFD) and tested whether choline deficiency (CD) represented an underlying mechanism contributing to their phenotype. HFD-fedEnpp6/ mice exhibited selectively reduced visceral adiposity with higher white adipose expression of “beigeing” markers (indicative of enhanced lipid burning), improved glucose tolerance and resistance to fatty liver compared to Enpp6+/+ mice. HFD-fed Enpp6/ mice also exhibited significantly decreased hepatic choline levels and evidence for impaired de novo phosphatidylcholine biosynthesis through reduced hepatic phosphatidylethanolamine N-Methyltransferase (Pemt) expression. Dietary choline supplementation reversed the improved metabolic phenotype of Enpp6/ mice in parallel with restored hepatic Pemt mRNA levels. Dietary choline deficiency (CD) did not augment the improved phenotype of HFD-fed Enpp6/ mice. Instead, CD-HFD increased liver fat accumulation to a greater extent in Enpp6/ mice. This suggests ENPP6-regulated endogenous choline production plays a novel role in body-fat distribution distinct to dietary choline. ENPP6 is a novel anti-visceral obesity target through its effects on endogenous hepatic choline production.
- 18 October 2021
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 77
Hepatic choline deficiency underpins amelioration of visceral obesity and diabetes in ectonucleotide pyrophosphatase (Enpp)-6-/- mice
The global prevalence of obesity continues to rise, creating a growing need for new effective medicines. Selective targeting of visceral obesity (fat around the internal organs) would be particularly advantageous because it carries a greater risk for cardiometabolic diseases. The ectonucleotide pyrophosphatase (ENPP) enzyme family participates in several pathological conditions including diabetes (ENPP1, and ENPP2, also known as autotaxin) and vascular dysfunction (ENPP3-4). Of these, ENPP6 is a lysophospholipase-C-type enzyme recently linked to regulation of local phosphocholine availability. The role of ENPP6 in fat distribution and metabolism in the context of obesity is unknown. Here we investigated the metabolic profile of mice lacking the Enpp6 gene (Enpp6/) when exposed to an obesogenic high-fat-diet (HFD) and tested whether choline deficiency (CD) represented an underlying mechanism contributing to their phenotype. HFD-fedEnpp6/ mice exhibited selectively reduced visceral adiposity with higher white adipose expression of “beigeing” markers (indicative of enhanced lipid burning), improved glucose tolerance and resistance to fatty liver compared to Enpp6+/+ mice. HFD-fed Enpp6/ mice also exhibited significantly decreased hepatic choline levels and evidence for impaired de novo phosphatidylcholine biosynthesis through reduced hepatic phosphatidylethanolamine N-Methyltransferase (Pemt) expression. Dietary choline supplementation reversed the improved metabolic phenotype of Enpp6/ mice in parallel with restored hepatic Pemt mRNA levels. Dietary choline deficiency (CD) did not augment the improved phenotype of HFD-fed Enpp6/ mice. Instead, CD-HFD increased liver fat accumulation to a greater extent in Enpp6/ mice. This suggests ENPP6-regulated endogenous choline production plays a novel role in body-fat distribution distinct to dietary choline. ENPP6 is a novel anti-visceral obesity target through its effects on endogenous hepatic choline production.
- 2 November 2018
- Published by Bioscientifica in Endocrine Abstracts
Time-dependent cortisol turnover in tissues using stable isotope tracers and MALDI Mass Spectrometry (MS) sampling
Excess action of glucocorticoid hormones is implicated in metabolic disease and cognitive decline, 11β-hydroxysteroid dehydrogenase 1 (11βHSD1) catalysing generation of active glucocorticoid hormones in tissues. The penetration rates and tissue-specific contribution of 11βHSD1 to glucocorticoid turnover were assessed using tracer kinetics. 9,11,12,12-d4-Cortisol (d4F) was infused (1.75 mg/day, 7 days) into C57Bl6/J male mice and mice lacking 11βHSD1 (n=3/group). Regeneration of d3F by 11βHSD1-mediated reduction was assessed in plasma by LC-MS/MS and in tissues using matrix assisted laser desorption ionisation (MALDI) MS. Mean±SEM. Circulating concentrations of d4F were 936±45 nM at 24 h, reducing to 566±63 nM at 48 h, and remaining steady until 7days, suggesting an initial stimulation of clearance (or changes in infusion rate). This pattern was mirrored in liver; d4F was detected at 6 h, increasing to 24 h and then plateaued at a lower level (~75% of 24 h) by 48 h. d4F was detectable in brain by 6 h, reaching steady state by 24 h, 3.5 fold lower than liver. Tracer was not detected in adipose until 24 h, remaining steady (4 fold lower than liver) until 7 days. D3F was detected in plasma, liver and brain at 6 h, but only after 48 h in adipose. Again in plasma and liver the amounts of d3F peaked at 24 h and declined to steady state at 48 h. D3F abundance in adipose and brain did not change from 24 h to 7days. Regeneration of d3F was abolished in mice lacking 11βHSD1, without changing circulating or tissue levels of d4F. Glucocorticoid regeneration of d3F is mediated solely by 11βHSD1 and circulating levels largely mirror hepatic production. Less glucocorticoid is regenerated in brain and adipose and levels are less dependent of the circulating pool, demonstrating the important contribution of the local enzyme and the importance of targeting therapies to specific tissues, such as brain.
- 2 November 2018
- Published by Bioscientifica in Endocrine Abstracts
Time-dependent cortisol turnover in tissues using stable isotope tracers and MALDI Mass Spectrometry (MS) sampling
Excess action of glucocorticoid hormones is implicated in metabolic disease and cognitive decline, 11β-hydroxysteroid dehydrogenase 1 (11βHSD1) catalysing generation of active glucocorticoid hormones in tissues. The penetration rates and tissue-specific contribution of 11βHSD1 to glucocorticoid turnover were assessed using tracer kinetics. 9,11,12,12-d4-Cortisol (d4F) was infused (1.75 mg/day, 7 days) into C57Bl6/J male mice and mice lacking 11βHSD1 (n=3/group). Regeneration of d3F by 11βHSD1-mediated reduction was assessed in plasma by LC-MS/MS and in tissues using matrix assisted laser desorption ionisation (MALDI) MS. Mean±SEM. Circulating concentrations of d4F were 936±45 nM at 24 h, reducing to 566±63 nM at 48 h, and remaining steady until 7days, suggesting an initial stimulation of clearance (or changes in infusion rate). This pattern was mirrored in liver; d4F was detected at 6 h, increasing to 24 h and then plateaued at a lower level (~75% of 24 h) by 48 h. d4F was detectable in brain by 6 h, reaching steady state by 24 h, 3.5 fold lower than liver. Tracer was not detected in adipose until 24 h, remaining steady (4 fold lower than liver) until 7 days. D3F was detected in plasma, liver and brain at 6 h, but only after 48 h in adipose. Again in plasma and liver the amounts of d3F peaked at 24 h and declined to steady state at 48 h. D3F abundance in adipose and brain did not change from 24 h to 7days. Regeneration of d3F was abolished in mice lacking 11βHSD1, without changing circulating or tissue levels of d4F. Glucocorticoid regeneration of d3F is mediated solely by 11βHSD1 and circulating levels largely mirror hepatic production. Less glucocorticoid is regenerated in brain and adipose and levels are less dependent of the circulating pool, demonstrating the important contribution of the local enzyme and the importance of targeting therapies to specific tissues, such as brain.
- Open Access
Kynurenine 3-monooxygenase (KMO) is a critical regulator of renal ischemia-reperfusion injury
SUMMARY: Acute kidney injury (AKI) following ischemia-reperfusion injury (IRI) has a high mortality and lacks specific therapies. Here, we report that mice lacking kynurenine 3-monooxygenase (KMO) activity ( Kmo null mice) are protected against AKI after renal IRI. This advances our previous work showing that KMO blockade protects against acute lung injury and AKI in experimental multiple organ failure caused by acute pancreatitis. We show that KMO is highly expressed in the kidney and exerts major metabolic control over the biologically-active kynurenine metabolites 3-hydroxykynurenine, kynurenic acid and downstream metabolites. In experimental AKI induced by unilateral kidney IRI, Kmo null mice had preserved renal function, reduced renal tubular cell injury, and fewer infiltrating neutrophils compared to wild-type ( Kmo wt ) control mice. Together, these data confirm that flux through KMO contributes to AKI after IRI, and supports the rationale for KMO inhibition as a therapeutic strategy to protect against AKI during critical illness.
Open AccessKynurenine 3-monooxygenase (KMO) is a critical regulator of renal ischemia-reperfusion injury
SUMMARY: Acute kidney injury (AKI) following ischemia-reperfusion injury (IRI) has a high mortality and lacks specific therapies. Here, we report that mice lacking kynurenine 3-monooxygenase (KMO) activity ( Kmo null mice) are protected against AKI after renal IRI. This advances our previous work showing that KMO blockade protects against acute lung injury and AKI in experimental multiple organ failure caused by acute pancreatitis. We show that KMO is highly expressed in the kidney and exerts major metabolic control over the biologically-active kynurenine metabolites 3-hydroxykynurenine, kynurenic acid and downstream metabolites. In experimental AKI induced by unilateral kidney IRI, Kmo null mice had preserved renal function, reduced renal tubular cell injury, and fewer infiltrating neutrophils compared to wild-type ( Kmo wt ) control mice. Together, these data confirm that flux through KMO contributes to AKI after IRI, and supports the rationale for KMO inhibition as a therapeutic strategy to protect against AKI during critical illness.
- Open Access
Exploring N-acyl-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-enes as 11β-HSD1 Inhibitors
We recently found that a cyclohexanecarboxamide derived from 4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-ene displayed low nanomolar inhibition of 11β-HSD1. In continuation of our efforts to discover potent and selective 11β-HSD1 inhibitors, herein we explored several replacements for the cyclohexane ring. Some derivatives exhibited potent inhibitory activity against human 11β-HSD1, although with low selectivity over the isoenzyme 11β-HSD2, and poor microsomal stability.
Open AccessExploring N-acyl-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-enes as 11β-HSD1 Inhibitors
We recently found that a cyclohexanecarboxamide derived from 4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-ene displayed low nanomolar inhibition of 11β-HSD1. In continuation of our efforts to discover potent and selective 11β-HSD1 inhibitors, herein we explored several replacements for the cyclohexane ring. Some derivatives exhibited potent inhibitory activity against human 11β-HSD1, although with low selectivity over the isoenzyme 11β-HSD2, and poor microsomal stability.
- Open Access
- 1 February 2018
- Published by Elsevier in Biochemical Pharmacology
- Vol. 148, 88-99
Quantification of 11β-hydroxysteroid dehydrogenase 1 kinetics and pharmacodynamic effects of inhibitors in brain using mass spectrometry imaging and stable-isotope tracers in mice
- 1 February 2018
- Published by Elsevier in Biochemical Pharmacology
- Vol. 148, 88-99
Open AccessQuantification of 11β-hydroxysteroid dehydrogenase 1 kinetics and pharmacodynamic effects of inhibitors in brain using mass spectrometry imaging and stable-isotope tracers in mice
- Open Access
- 1 October 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 139, 412-428
Design, synthesis and in vivo study of novel pyrrolidine-based 11β-HSD1 inhibitors for age-related cognitive dysfunction
- 1 October 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 139, 412-428
Open AccessDesign, synthesis and in vivo study of novel pyrrolidine-based 11β-HSD1 inhibitors for age-related cognitive dysfunction
- Open Access
- 7 September 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 10806
In search of a small molecule agonist of the relaxin receptor RXFP1 for the treatment of liver fibrosis
The peptide hormone human relaxin-2 (H2-RLX) has emerged as a potential therapy for cardiovascular and fibrotic diseases, but its short in vivo half-life is an obstacle to long-term administration. The discovery of ML290 demonstrated that it is possible to identify small molecule agonists of the cognate G-protein coupled receptor for H2-RLX (relaxin family peptide receptor-1 (RXFP1)). In our efforts to generate a new medicine for liver fibrosis, we sought to identify improved small molecule functional mimetics of H2-RLX with selective, full agonist or positive allosteric modulator activity against RXFP1. First, we confirmed expression of RXFP1 in human diseased liver. We developed a robust cellular cAMP reporter assay of RXFP1 signaling in HEK293 cells transiently expressing RXFP1. A high-throughput screen did not identify further specific agonists or positive allosteric modulators of RXFP1, affirming the low druggability of this receptor. As an alternative approach, we generated novel ML290 analogues and tested their activity in the HEK293-RXFP1 cAMP assay and the human hepatic cell line LX-2. Differences in activity of compounds on cAMP activation compared with changes in expression of fibrotic markers indicate the need to better understand cell- and tissue-specific signaling mechanisms and their disease-relevant phenotypes in order to enable drug discovery.
- 7 September 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 10806
Open AccessIn search of a small molecule agonist of the relaxin receptor RXFP1 for the treatment of liver fibrosis
The peptide hormone human relaxin-2 (H2-RLX) has emerged as a potential therapy for cardiovascular and fibrotic diseases, but its short in vivo half-life is an obstacle to long-term administration. The discovery of ML290 demonstrated that it is possible to identify small molecule agonists of the cognate G-protein coupled receptor for H2-RLX (relaxin family peptide receptor-1 (RXFP1)). In our efforts to generate a new medicine for liver fibrosis, we sought to identify improved small molecule functional mimetics of H2-RLX with selective, full agonist or positive allosteric modulator activity against RXFP1. First, we confirmed expression of RXFP1 in human diseased liver. We developed a robust cellular cAMP reporter assay of RXFP1 signaling in HEK293 cells transiently expressing RXFP1. A high-throughput screen did not identify further specific agonists or positive allosteric modulators of RXFP1, affirming the low druggability of this receptor. As an alternative approach, we generated novel ML290 analogues and tested their activity in the HEK293-RXFP1 cAMP assay and the human hepatic cell line LX-2. Differences in activity of compounds on cAMP activation compared with changes in expression of fibrotic markers indicate the need to better understand cell- and tissue-specific signaling mechanisms and their disease-relevant phenotypes in order to enable drug discovery.
- Open Access
- 27 June 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 4299
Long-term cilostazol treatment reduces gliovascular damage and memory impairment in a mouse model of chronic cerebral hypoperfusion
Chronic cerebral hypoperfusion is a major cause of age-related vascular cognitive impairment. A well-characterised mouse model has shown that hypoperfusion results in gliovascular and white matter damage and impaired spatial working memory. In this study, we assessed whether cilostazol, a phosphodiesterase III inhibitor, could protect against these changes. Adult, male C57Bl/6J mice were subjected to bilateral common carotid artery stenosis or a sham operation and fed normal or cilostazol diet for three months. Cilostazol treatment reduced the impairment in working memory and white matter function after hypoperfusion. Endothelial adhesion molecules and gliosis, increased after hypoperfusion, were ameliorated with cilostazol treatment. Interestingly, the improvement in working memory was closely correlated with reduced microglia and endothelial adhesion molecules. Further, the number of stroke lesions after hypoperfusion was reduced in the cilostazol-treated group. Altogether cilostazol showed potential to ameliorate the gliovascular damage and working memory impairments after hypoperfusion possibly via endothelial protection supporting its potential use in the treatment of vascular cognitive impairment.
- 27 June 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 4299
Open AccessLong-term cilostazol treatment reduces gliovascular damage and memory impairment in a mouse model of chronic cerebral hypoperfusion
Chronic cerebral hypoperfusion is a major cause of age-related vascular cognitive impairment. A well-characterised mouse model has shown that hypoperfusion results in gliovascular and white matter damage and impaired spatial working memory. In this study, we assessed whether cilostazol, a phosphodiesterase III inhibitor, could protect against these changes. Adult, male C57Bl/6J mice were subjected to bilateral common carotid artery stenosis or a sham operation and fed normal or cilostazol diet for three months. Cilostazol treatment reduced the impairment in working memory and white matter function after hypoperfusion. Endothelial adhesion molecules and gliosis, increased after hypoperfusion, were ameliorated with cilostazol treatment. Interestingly, the improvement in working memory was closely correlated with reduced microglia and endothelial adhesion molecules. Further, the number of stroke lesions after hypoperfusion was reduced in the cilostazol-treated group. Altogether cilostazol showed potential to ameliorate the gliovascular damage and working memory impairments after hypoperfusion possibly via endothelial protection supporting its potential use in the treatment of vascular cognitive impairment.